COMMUNIQUÉS West-GlobeNewswire

IBA – ACQUISITION OF OWN SHARES
05/05/2025
Immediate Release – May 5 th , 2025 Louvain-la-Neuve, Belgium, May 5 th , 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam [...]
IBA – ACQUISITION D’ACTIONS PROPRES
05/05/2025
Publication immédiate – 5 mai 2025 Louvain-la-Neuve, Belgique, 5 mai 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam [...]
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
05/05/2025
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, [...]
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab
05/05/2025
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab Lusvertikimab well tolerated over the 24-week additional treatment period. Oral [...]
OSE Immunotherapeutics annonce que plus de 90% des patients répondeurs ont maintenu une rémission symptomatique pendant la période d’extension sous Lusvertikimab
05/05/2025
OSE Immunotherapeutics annonce que plus de 90 % des patients répondeurs ont maintenu une rémission symptomatique pendant la période d’extension sous Lusvertikimab Bonne tolérance de Lusvertikimab pendant les 24 semaines [...]
Cuprina Holdings Announces Completion, Receipt of Certification and License, for IVF Media Production Facility Built in Collaboration with Ferti-Craft Pte Ltd.
05/05/2025
SINGAPORE, May 05, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“ Cuprina ” or “the Company ”), a biomedical and biotechnology company dedicated to the development and commercialization of [...]
Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering
05/05/2025
SINGAPORE, May 05, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“ CUPR ” or “the Company ”), a biomedical and biotechnology company dedicated to the development and commercialization of [...]
Cuprina Holdings (Cayman) Limited Announces Pricing of $12 million Initial Public Offering
05/05/2025
SINGAPORE, May 05, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (“ CUPR ” or “the Company ”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the [...]
AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting
05/05/2025
PRESS RELEASE AB SCIENCE TO PRESENT NEW DATA FROM MASITINIB CLINICAL PROGRAM IN AMYOTROPHIC LATERAL SCLEROSIS IN TWO PRESENTATIONS AT THE 2025 ENCALS ANNUAL MEETING MASITINIB REDUCES SERUM NEUROFILAMENT LIGHT CHAIN (NFL [...]
AB Science présentera lors de la réunion annuelle de l’ENCALS en 2025 de nouvelles données issues du programme de développement clinique du masitinib dans la SLA
05/05/2025
COMMUNIQUE DE PRESSE AB SCIENCE PRÉSENTERA LORS DE LA RÉUNION ANNUELLE DE L'ENCALS EN 2025 DE NOUVELLES DONNÉES ISSUES DU PROGRAMME DE DEVELOPPEMENT CLINIQUE DU MASITINIB DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE LE [...]
Coloplast A/S CEO Kristian Villumsen steps down as of today
05/05/2025
Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy period, the Board [...]
Arialief Reviews (CRITICAL INVESTIGATION) What Doctors Say About Arialief's Safety And Complaints!
05/05/2025
ALBANY, N.Y., May 05, 2025 (GLOBE NEWSWIRE) -- Arialief is a thoughtfully designed natural nerve pain relief supplement that can address the root issues behind various symptoms associated with neuropathy. It is backed [...]
Arialief Side Effects Investigated: Review the User Complaints, Top Benefits & Ingredients List Before Buy!
05/05/2025
New Review Explores Arialief’s Side Effects, Complaints, Ingredients, and Nerve-Calming Formula for Neuropathy Relief ALBANY, N.Y., May 05, 2025 (GLOBE NEWSWIRE) -- If you’re reading this, chances are you, or someone [...]
Cuprina Holdings Announces Completion, Receipt of Certification and License, for IVF Media Production Facility Built in Collaboration with Ferti-Craft Pte Ltd.
05/05/2025
SINGAPORE, May 05, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“ Cuprina ” or “the Company ”), a biomedical and biotechnology company dedicated to the development and commercialization of [...]
MicroRNAs Research Initiative in Glioblastoma Stem Cells Awarded $85K by Brain Cancer Canada
05/05/2025
TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Brain Cancer Canada is pleased to announce a $85,000 grant for a cutting-edge research initiative led by Dr. Leonardo Salmena at the University of Toronto. The project, titled [...]
Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference
05/05/2025
BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
05/05/2025
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 5 May 2025 at 17:00 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
BioSig Enters into an LOI to Merge with Streamex Exchange Corp.
05/05/2025
Los Angeles, May 05, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company is pleased to announce it has entered into a Letter of Intent (“LOI”) to [...]
Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial
05/05/2025
In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months. SOUTH JORDAN, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- [...]

Pages